Trial Profile

Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary) ; 1 Phosphatidylinositol 3 kinase inhibitors; Antiandrogens; ERBB 2 receptor antagonists; Fibroblast growth factor receptor antagonists; Mitogen-activated protein kinase kinase inhibitors; Notch receptor antagonists; Proto-oncogene protein c-kit inhibitors
Indications Adenoid cystic carcinoma; Salivary gland cancer
Focus Therapeutic Use

Most Recent Events

05 Jan 2024 Status changed from recruiting to active, no longer recruiting.
18 Feb 2022 Planned number of patients changed from 30 to 200.
26 Nov 2021 Planned End Date changed from 1 Feb 2020 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com